Skip to main content
Fig. 7 | Experimental Hematology & Oncology

Fig. 7

From: A novel and efficient CD22 CAR-T therapy induced a robust antitumor effect in relapsed/refractory leukemia patients when combined with CD19 CAR-T treatment as a sequential therapy

Fig. 7

Analysis of CD19 and CD22 cell-surface expression in three patients at pretreatment and relapsed stage. BMMCs from patients before CAR-T cells infusion and relapsed after immunotherapy were obtained, stained with CD45, CD34, CD10, CD33, CD19 and CD22 and analyzed by flow cytometry. Leukemia blasts were gated via CD45/SSC two parameters graph and subgated in CD34 or CD10, followed by analysis of surface expression of CD19 and CD22 on gated cells. Red dots represent leukemia blasts. Black dots represent normal cells. a, b and e. Flow cytometry analysis of BMMCs samples from 3 patients at pretreatment and relapse stage, including patient 4 (a), patient 3 (b) and patient 2 (e). c. CD19 expression in patient 3 by histogram analysis at pretreatment and relapse stage indicated loss of CD19 antigen during treatment. d Histogram analysis of CD22 on BMMCs samples from patient 3 before CAR-T cells infusion and relapse stage showed CD22 downregulation

Back to article page